Nasdaq
$25.41▲ 0.26%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.64BShares out 100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
23- 10.15After-hours26.10.16 06:004Ownership#●●●#●●●
Nurix Therapeutics, Inc.
Nurix Therapeutics executive Gwenn Hansen filed a Form 4 on October 15, 2026, reporting a change in beneficial ownership of securities. This filing serves as a standard disclosure regarding the insider's stock holdings.…more
$25.41+0.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:14144Ownership
Nurix Therapeutics, Inc.
Insider Gregory Julia P of Nurix Therapeutics, Inc. filed an SEC Form 144 on October 14, 2026, to report a proposed sale of company securities. This filing serves as a formal notification of the insider's intent to dispose of shares.…more
$25.41+0.26%vs prev closeView filingShare - 10.14After-hours26.10.15 05:114Ownership
Nurix Therapeutics, Inc.
Insider Julia P. Gregory of Nurix Therapeutics, Inc. filed a Form 4 on October 14, 2026, reporting a change in beneficial ownership of securities. This filing serves as an official disclosure of insider transaction activity to the SEC.…more
$25.41+0.26%vs prev closeView filingShare
22 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12After-hours26.10.13 05:05Bullish#●●●#●●●#●●●
Nurix Therapeutics Reports Q3 Profit Driven by Roche Collaboration
Nurix Therapeutics achieved a profit in the third quarter, bolstered by significant license revenue from its collaboration with Roche. The company also advanced its lead candidate bexobrutideg into Phase 3 trials and maintains a strong cash position of $1.1 billion.…more
$25.41+0.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.7Overnight26.10.07 14:00
●●●●●●●● ●●●●● ●●●●●●
Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 clinical trial evaluating its BTK degrader in combination with venetoclax for chronic lymphocytic leukemia. The study, conducted in collaboration with Roche, aims to assess the safety and clinical activity of this combination regimen.…more
$25.41+0.26%vs prev close - 10.5Pre-market26.10.05 20:10
●●●●●●●● ●●●●● ●●●●●●
Nurix Therapeutics has extended its oncology research collaboration with Gilead Sciences for an additional two years, securing a $10 million extension fee. While the deal underscores the ongoing partnership, it remains a research-stage development rather than a direct commercial revenue milestone.…more
$25.41+0.26%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report